Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.

about

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.

Item

http://www.wikidata.org/entity/Q36371597

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Analysis of genotypic and phen ...... ritonavir-boosted saquinavir.

@ast

Analysis of genotypic and phen ...... ritonavir-boosted saquinavir.

@en

type

Item

label

Analysis of genotypic and phen ...... ritonavir-boosted saquinavir.

@ast

Analysis of genotypic and phen ...... ritonavir-boosted saquinavir.

@en

prefLabel

Analysis of genotypic and phen ...... ritonavir-boosted saquinavir.

@ast

Analysis of genotypic and phen ...... ritonavir-boosted saquinavir.

@en

P1476

Analysis of genotypic and phen ...... ritonavir-boosted saquinavir.

@en

P2093

Clotet B

http://www.w3.org/2001/XMLSchema#string

Hill A

http://www.w3.org/2001/XMLSchema#string

Molto J

http://www.w3.org/2001/XMLSchema#string

Walmsley S

http://www.w3.org/2001/XMLSchema#string

P2860

Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults

Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

In vitro antiviral interaction of lopinavir with other protease inhibitors.

Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.

P304

67-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1468-1293.2006.00351.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7352837

http://www.w3.org/2001/XMLSchema#string

P698

16420251

http://www.w3.org/2001/XMLSchema#string